SYS-CON MEDIA Authors: Bob Gourley, Sandi Mappic, Eric Brown, RealWire News Distribution, Kevin Benedict

News Feed Item

MedX Health Corp. Announces First Quarter 2014 Financial Results

MISSISSAUGA, ONTARIO -- (Marketwired) -- 05/29/14 -- MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX) announced its results for the three months ended March 31, 2014, which are also available on SEDAR (www.sedar.com).

The Company reported a loss of $268,732, or $0.00 per share for the three months ended March 31, 2014, compared with a loss of $348,668, or $0.01 per share for three months ended March 31, 2013. Revenues of $157,772 for the first quarter of 2014 were higher than $119,429 in 2013, due in part to increased revenue from the Company's SIAscopy product line.

"During the first quarter the company received the CE Mark for its SIAscopy products which allows it to start marketing its skin cancer screening technology in Europe again," said Rob von der Porten, CEO. "In addition, through our relationship with a distributor in Australia, an application process has started for certification in Australia, where SIAscopy products have been sold successfully in the past. Consequently, we believe we will see increased revenue from our skin cancer screening products in the future," he continued.

About MedX

MedX is headquartered in Mississauga, Ontario (Toronto), and is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technologies for use in numerous medical settings, including rehab/chiropractic, dental, wound care, and veterinary medicine, providing patients with drug free and non-invasive treatment of tissue damage and pain. MedX laser and light products are FDA approved, Health Canada cleared, and CE Mark approved for use in North America as well as the European Union. MedX's products include SIMSYS(TM) and MoleMate(TM), which are approved by Health Canada, and available to Canadian physicians and dermatologists, are FDA approved for use in the USA and are currently under review for CE approval for use in Europe, the UK, and Australia, as an optical biopsy that uses patented technology featuring a hand-held scanner device designed for clinical use that utilizes light to view beneath suspicious moles or lesions in a pain free, non-invasive manner, creating images in real-time for physicians and dermatologists to evaluate all types of moles or lesions within seconds. For more information log onto www.simsys-molemate.com. For a complete profile of MedX and its products visit www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.